LOC100507412: A Drug Target / Disease Biomarker (G100507412)
LOC100507412: A Drug Target / Disease Biomarker
LOC100507412 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoplasmic proteins, which are involved in various cellular processes. One of the unique features of LOC100507412 is its ability to interact with other proteins, leading to its potential as a drug target or biomarker.
The protein encoded by LOC100507412 is made up of 1,942 amino acids and has a calculated molecular weight of 21.9 kDa. It is localized to the endoplasmic reticulum and can be expressed in various cell types, including neurons, glial cells, and immune cells. LOC100507412 is also known to interact with several protein partners, including the protein encoded by the gene PDGF-R2.
The interaction between LOC100507412 and PDGF-R2 is a critical step in the regulation of cellular processes that are critical for normal development, wound healing, and tissue repair. PDGF-R2 is a potent growth factor that plays a central role in the development and maintenance of tissues, including neural tissues. In addition to its role in cell growth and development, PDGF-R2 is also involved in the regulation of pain perception and neurodegenerative diseases.
The ability of LOC100507412 to interact with PDGF-R2 has led to its potential as a drug target or biomarker. By inhibiting the activity of PDGF-R2, LOC100507412 may be able to treat conditions that are caused by the over-production or dysfunction of PDGF-R2. For example, LOC100507412 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. By targeting LOC100507412, researchers may be able to develop new treatments for these debilitating conditions.
In addition to its potential as a drug target or biomarker, LOC100507412 may also be a useful marker for certain types of cancer. The over-production or dysfunction of PDGF-R2 has been implicated in the development of many types of cancer, including neuro cancer. By detecting the expression of LOC100507412 in cancer cells, researchers may be able to identify new targets for cancer treatment.
The structure and function of LOC100507412 are of great interest from a fundamental biological perspective. The protein is composed of a unique arrangement of secondary structure elements, including a long alpha-helic acid domain and a short beta-sheet. The alpha-helic acid domain is responsible for the protein's ability to interact with PDGF-R2, while the beta-sheet is involved in the protein's stability and functions as a protein.
In addition to its unique structure, LOC100507412 has also been shown to play a role in the regulation of cellular processes that are critical for normal development and function. For example, LOC100507412 has been shown to be involved in the regulation of cell adhesion, which is critical for the formation of tissues and organs during development. In addition, LOC100507412 has also been shown to be involved in the regulation of cell survival, which is critical for the regulation of cellular processes that are essential for normal development and function.
In conclusion, LOC100507412 is a protein that is of great interest from a fundamental biological perspective. Its unique structure and function, as well as its ability to interact with PDGF-R2, make it a promising candidate as a drug target or biomarker. Further research is needed to fully understand the role of LOC100507412 in cellular processes and its potential as a treatment for
Protein Name: Uncharacterized LOC100507412
The "LOC100507412 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC100507412 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC100507424 | LOC100507443 | LOC100507513 | LOC100507520 | LOC100507547 | LOC100507577 | LOC100507656 | LOC100509646 | LOC100533709 | LOC100630923 | LOC100652743 | LOC100652768 | LOC100652833 | LOC100652999 | LOC100653061 | LOC100996385 | LOC100996412 | LOC100996583 | LOC100996637 | LOC100996643 | LOC100996664 | LOC100996770 | LOC101060017 | LOC101060106 | LOC101060179 | LOC101060400 | LOC101060445 | LOC101060524 | LOC101060632 | LOC101448202 | LOC101593348 | LOC101926887 | LOC101926948 | LOC101926953 | LOC101926959 | LOC101926969 | LOC101927002 | LOC101927020 | LOC101927025 | LOC101927026 | LOC101927040 | LOC101927053 | LOC101927060 | LOC101927066 | LOC101927082 | LOC101927108 | LOC101927143 | LOC101927164 | LOC101927166 | LOC101927169 | LOC101927179 | LOC101927188 | LOC101927199 | LOC101927216 | LOC101927243 | LOC101927245 | LOC101927253 | LOC101927263 | LOC101927269 | LOC101927314 | LOC101927369 | LOC101927394 | LOC101927421 | LOC101927476 | LOC101927483 | LOC101927495 | LOC101927518 | LOC101927531 | LOC101927548 | LOC101927550 | LOC101927571 | LOC101927588 | LOC101927598 | LOC101927605 | LOC101927609 | LOC101927627 | LOC101927636 | LOC101927668 | LOC101927712 | LOC101927727 | LOC101927741 | LOC101927745 | LOC101927770 | LOC101927787 | LOC101927825 | LOC101927827 | LOC101927834 | LOC101927840 | LOC101927853 | LOC101927855 | LOC101927857 | LOC101927863 | LOC101927896 | LOC101927897 | LOC101927910 | LOC101927932 | LOC101927942 | LOC101927947 | LOC101927960 | LOC101927967
